Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [3] - The company's lead product is Ampligen (rintatolimod), a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials [3] Event Announcement - AIM ImmunoTech will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech, which will be held virtually from August 19-21, 2025 [1] - The presentation is scheduled for August 20, 2025, at 2:40 PM ET, and will be led by Thomas Equels, the Chief Executive Officer, President & Executive Vice Chairman of the company [1]

Group 1 - AIM ImmunoTech Inc. announced the closing of a public offering of 2,000,000 shares of common stock and accompanying warrants at a combined public offering price of $4.00 per share, resulting in gross proceeds of approximately $8.0 million before expenses [1][2][3] - The offering included Class E and Class F warrants, both of which are exercisable immediately upon issuance, with Class E warrants expiring on the fifth anniversary and Class F warrants expiring on the eighteen-month anniversary of the original issuance date [1] - Maxim Group LLC acted as the sole placement agent for this offering [2] Group 2 - AIM ImmunoTech Inc. is focused on the research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [4] - The company's lead product is Ampligen® (rintatolimod), which is a first-in-class investigational drug with broad-spectrum activity in clinical trials [4]

Core Viewpoint - AIM ImmunoTech Inc. has announced the withdrawal of its delisting determination by NYSE Regulation, allowing its common stock to resume trading on the NYSE American starting June 17, 2025 [1] Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company focused on developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [2] - The company's lead product is Ampligen (rintatolimod), a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator, showing broad-spectrum activity in clinical trials [2]

Core Insights - AIM ImmunoTech Inc. presented clinical trial data for its drug Ampligen at the Annual Meeting of the American Association of Immunologists, highlighting its potential in treating cancers and immune disorders [1][2]. Company Overview - AIM ImmunoTech Inc. is focused on developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19. Its lead product, Ampligen (rintatolimod), is a first-in-class investigational drug that acts as a highly selective TLR3 agonist [3]. Clinical Data Presentation - The presentation by Dr. Pawel Kalinski discussed the unique selectivity of Ampligen in promoting CTL (cytotoxic T lymphocyte) influx into the tumor microenvironment (TME) while avoiding Treg (regulatory T cell) attraction. This selectivity differentiates Ampligen from other treatments like poly-I:C [2]. - Mechanistic data indicated that Ampligen's selectivity is due to its avoidance of helicase-dependent activation of NFkB, which prevents the induction of undesirable inflammatory factors while focusing on tumor tissues [2]. CEO Commentary - The CEO of AIM ImmunoTech expressed confidence in Ampligen's potential as a therapeutic option for unmet medical needs, particularly in the context of deadly cancers [3].